Almitas Capital LLC Purchases New Stake in Alector, Inc. (NASDAQ:ALEC)

Almitas Capital LLC bought a new position in shares of Alector, Inc. (NASDAQ:ALEC - Free Report) during the 4th quarter, according to the company in its most recent filing with the SEC. The fund bought 284,845 shares of the company's stock, valued at approximately $538,000. Almitas Capital LLC owned 0.29% of Alector at the end of the most recent quarter.

Other large investors have also recently bought and sold shares of the company. Tower Research Capital LLC TRC grew its stake in shares of Alector by 71.1% during the 4th quarter. Tower Research Capital LLC TRC now owns 14,670 shares of the company's stock worth $28,000 after purchasing an additional 6,096 shares during the period. Vontobel Holding Ltd. increased its holdings in Alector by 127.3% in the fourth quarter. Vontobel Holding Ltd. now owns 25,000 shares of the company's stock valued at $47,000 after buying an additional 14,000 shares in the last quarter. Apollon Wealth Management LLC acquired a new stake in shares of Alector during the 4th quarter valued at approximately $47,000. RPO LLC purchased a new stake in shares of Alector during the 4th quarter worth approximately $50,000. Finally, Intech Investment Management LLC increased its stake in Alector by 83.5% in the 4th quarter. Intech Investment Management LLC now owns 35,382 shares of the company's stock valued at $67,000 after purchasing an additional 16,096 shares in the last quarter. Hedge funds and other institutional investors own 85.83% of the company's stock.

Alector Trading Up 6.6 %

NASDAQ:ALEC traded up $0.08 on Friday, hitting $1.30. 1,281,778 shares of the stock were exchanged, compared to its average volume of 805,773. The stock has a fifty day moving average of $1.23 and a 200-day moving average of $2.21. The stock has a market cap of $128.81 million, a PE ratio of -0.76 and a beta of 0.73. Alector, Inc. has a fifty-two week low of $0.87 and a fifty-two week high of $6.78.

Alector (NASDAQ:ALEC - Get Free Report) last issued its earnings results on Wednesday, February 26th. The company reported ($0.02) EPS for the quarter, beating analysts' consensus estimates of ($0.61) by $0.59. Alector had a negative net margin of 257.54% and a negative return on equity of 108.77%. The business had revenue of $54.24 million for the quarter, compared to the consensus estimate of $20.41 million. As a group, analysts predict that Alector, Inc. will post -1.88 earnings per share for the current year.

Analyst Upgrades and Downgrades

Several analysts have weighed in on ALEC shares. HC Wainwright reissued a "buy" rating and issued a $7.00 target price on shares of Alector in a report on Thursday, February 27th. Morgan Stanley reaffirmed an "underweight" rating and issued a $1.50 target price (down previously from $3.00) on shares of Alector in a research note on Friday, March 7th. Two equities research analysts have rated the stock with a sell rating, two have given a hold rating and three have assigned a buy rating to the stock. According to MarketBeat, Alector has a consensus rating of "Hold" and an average price target of $3.50.

Alector Profile

Alector, Inc, a clinical stage biopharmaceutical company, develops therapies for the treatment of neurodegeneration diseases. Its products include AL001, an immune activity in the brain with genetic links to multiple neurodegenerative disorders, which is in Phase III clinical trial for the treatment of frontotemporal dementia, Alzheimer's, Parkinson's, and amyotrophic lateral sclerosis diseases; and AL101 that is in Phase I clinical trial for the treatment of neurodegenerative diseases, including Alzheimer's and Parkinson's diseases.